Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial
Abstract Objective To assess the effectiveness and safety profiles of rivaroxaban compared to low molecular weight heparin (LMWH) in managing lower extremity deep vein thrombosis (DVT) subsequent to thoracoscopic lung cancer surgery. Methods Sixty patients diagnosed with lower extremity deep vein th...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Journal of Cardiothoracic Surgery |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13019-024-03225-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585466215399424 |
|---|---|
| author | Lidan Zhang Di Wu Liang Li Qin Zhao Hailing Yang Xiaoyong Han Liang Liu Lu Gao |
| author_facet | Lidan Zhang Di Wu Liang Li Qin Zhao Hailing Yang Xiaoyong Han Liang Liu Lu Gao |
| author_sort | Lidan Zhang |
| collection | DOAJ |
| description | Abstract Objective To assess the effectiveness and safety profiles of rivaroxaban compared to low molecular weight heparin (LMWH) in managing lower extremity deep vein thrombosis (DVT) subsequent to thoracoscopic lung cancer surgery. Methods Sixty patients diagnosed with lower extremity deep vein thrombosis (DVT) following thoracoscopic lung cancer surgery were randomly assigned to two groups: the experimental group comprising 30 patients treated with rivaroxaban, and the control group consisting of 30 patients treated with low molecular weight heparin (LMWH). The fundamental clinical characteristics of patients in both groups were documented, encompassing parameters, along with pre- and post-surgical lower limb vascular ultrasound findings. Additionally, variations in drainage volume over the initial three days following the procedure were also noted. Patients were subjected to a three-month follow-up period, during which data from one-month and three-month postoperative examinations were collected. Results Patients from both groups exhibited satisfactory wound healing postoperatively. D-dimer levels remained stable, and lower extremity vascular ultrasound evaluations showed no signs of additional thrombus formation. Moreover, there were no reported cases of distant postoperative complications such as pleural effusion, gingival bleeding, or gastrointestinal bleeding. Nonetheless, subcutaneous bruising was observed in six patients from the control group, all localized at the sites of LMWH injections. Conclusion Rivaroxaban demonstrates efficacy comparable to LMWH in patients with lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery, while exhibiting a superior safety profile compared to LMWH. |
| format | Article |
| id | doaj-art-f608606e6c464812bdf9566479fc38a0 |
| institution | Kabale University |
| issn | 1749-8090 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Cardiothoracic Surgery |
| spelling | doaj-art-f608606e6c464812bdf9566479fc38a02025-01-26T12:51:48ZengBMCJournal of Cardiothoracic Surgery1749-80902025-01-012011610.1186/s13019-024-03225-5Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trialLidan Zhang0Di Wu1Liang Li2Qin Zhao3Hailing Yang4Xiaoyong Han5Liang Liu6Lu Gao7Department of Nuclear Medicine, Baoding First Central HospitalDepartment of Thoracic Surgery, Baoding First Central HospitalDepartment of Thoracic Surgery, Baoding First Central HospitalDepartment of Thoracic Surgery, Baoding First Central HospitalDepartment of Thoracic Surgery, Baoding First Central HospitalDepartment of Thoracic Surgery, Baoding First Central HospitalDepartment of Thoracic Surgery, Baoding First Central HospitalDepartment of Thoracic Surgery, Baoding First Central HospitalAbstract Objective To assess the effectiveness and safety profiles of rivaroxaban compared to low molecular weight heparin (LMWH) in managing lower extremity deep vein thrombosis (DVT) subsequent to thoracoscopic lung cancer surgery. Methods Sixty patients diagnosed with lower extremity deep vein thrombosis (DVT) following thoracoscopic lung cancer surgery were randomly assigned to two groups: the experimental group comprising 30 patients treated with rivaroxaban, and the control group consisting of 30 patients treated with low molecular weight heparin (LMWH). The fundamental clinical characteristics of patients in both groups were documented, encompassing parameters, along with pre- and post-surgical lower limb vascular ultrasound findings. Additionally, variations in drainage volume over the initial three days following the procedure were also noted. Patients were subjected to a three-month follow-up period, during which data from one-month and three-month postoperative examinations were collected. Results Patients from both groups exhibited satisfactory wound healing postoperatively. D-dimer levels remained stable, and lower extremity vascular ultrasound evaluations showed no signs of additional thrombus formation. Moreover, there were no reported cases of distant postoperative complications such as pleural effusion, gingival bleeding, or gastrointestinal bleeding. Nonetheless, subcutaneous bruising was observed in six patients from the control group, all localized at the sites of LMWH injections. Conclusion Rivaroxaban demonstrates efficacy comparable to LMWH in patients with lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery, while exhibiting a superior safety profile compared to LMWH.https://doi.org/10.1186/s13019-024-03225-5D-dimerLower extremity deep vein thrombosisLow molecular weight heparinPost-thoracoscopic lung cancerRivaroxaban |
| spellingShingle | Lidan Zhang Di Wu Liang Li Qin Zhao Hailing Yang Xiaoyong Han Liang Liu Lu Gao Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial Journal of Cardiothoracic Surgery D-dimer Lower extremity deep vein thrombosis Low molecular weight heparin Post-thoracoscopic lung cancer Rivaroxaban |
| title | Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial |
| title_full | Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial |
| title_fullStr | Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial |
| title_full_unstemmed | Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial |
| title_short | Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial |
| title_sort | rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery a randomized controlled trial |
| topic | D-dimer Lower extremity deep vein thrombosis Low molecular weight heparin Post-thoracoscopic lung cancer Rivaroxaban |
| url | https://doi.org/10.1186/s13019-024-03225-5 |
| work_keys_str_mv | AT lidanzhang rivaroxabanversuslowmolecularweightheparinformanaginglowerextremitydeepveinthrombosisfollowingthoracoscopiclungcancersurgeryarandomizedcontrolledtrial AT diwu rivaroxabanversuslowmolecularweightheparinformanaginglowerextremitydeepveinthrombosisfollowingthoracoscopiclungcancersurgeryarandomizedcontrolledtrial AT liangli rivaroxabanversuslowmolecularweightheparinformanaginglowerextremitydeepveinthrombosisfollowingthoracoscopiclungcancersurgeryarandomizedcontrolledtrial AT qinzhao rivaroxabanversuslowmolecularweightheparinformanaginglowerextremitydeepveinthrombosisfollowingthoracoscopiclungcancersurgeryarandomizedcontrolledtrial AT hailingyang rivaroxabanversuslowmolecularweightheparinformanaginglowerextremitydeepveinthrombosisfollowingthoracoscopiclungcancersurgeryarandomizedcontrolledtrial AT xiaoyonghan rivaroxabanversuslowmolecularweightheparinformanaginglowerextremitydeepveinthrombosisfollowingthoracoscopiclungcancersurgeryarandomizedcontrolledtrial AT liangliu rivaroxabanversuslowmolecularweightheparinformanaginglowerextremitydeepveinthrombosisfollowingthoracoscopiclungcancersurgeryarandomizedcontrolledtrial AT lugao rivaroxabanversuslowmolecularweightheparinformanaginglowerextremitydeepveinthrombosisfollowingthoracoscopiclungcancersurgeryarandomizedcontrolledtrial |